פרוטלוס - Protelos
ש××× ×× !
×ת×ר××: 20.12.2015 ×תק××× ××××¢× ×× ×©××××§ ×תר××¤× ××פסק ×צ××ת×ת.
×ת×ר××: 20.12.2015 ×תק××× ××××¢× ×× ×©××××§ ×תר××¤× ××פסק ×צ××ת×ת.
××§×ר: ××©×¨× ××ר×××ת - ××××¢×ת ×¢× ×פסקת ש××××§ תר×פ×ת
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ×§×××¦× ×¤×¨××§×××××ת (ATC4) | M05BX Other drugs affecting bone structure and mineralization | |||||
|---|---|---|---|---|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||
| צ×רת ××ª× | פ××× - PER OS | |||||
| צ×רת ××× ×× | ××¨× ×××ת ×××× ×ª תר×××£ פ×××, GRANULES FOR ORAL SUSPENSION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||
| ×ת×××× | Treatment of severe osteoporosis in postmenopausal women, at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance. In postmenopausal women, strontium ranelate reduces the risk of vertebral and hip fractures.The decision to prescribe strontium ranelate should be based on an assessment of the individual patient's overall risks .
| |||||
× ×ª×× × ×¡× [ ×צ×× ]
| ||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
××× ×¢××× ×ר××¤× | |||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ×××××§×רפ××× | ער××× ×§×©×ר×× ×××××§×רפ××× |
|---|---|
| [ פר××××ס] ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | LES LABORATOIRES SERVIER, FRANCE |
| ×©× ××¢× ×ר×ש×× | MEDILINE LTD. |
| ר×ש××× | ת×ר×× ××ש×: 07/2008. ר×ש××× ×ת×ר××: 11/2014 |
| ת×ר×× ×¢×××× ××ר×× | 20.12.2015 |